This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in JAMA  Social Bookmarking   What's this?

Eric J. Topol, MD; James J. Ferguson, MD; Harlan F. Weisman, MD; James E. Tcheng, MD; Stephen G. Ellis, MD; Neal S. Kleiman, MD; Russell J. Ivanhoe, MD; Ann L. Wang; David P. Miller, MS; Keaven M. Anderson, PhD; Robert M. Califf, MD

JAMA. 1997;278(6):479-484.

Abstract
Context.
—Avciximab,lonal antibody fragment against the platelet receptor _llbβ₃ integrin, prevents platelet aggregation. A randomized, placebo-controlled study showed that abciximab improves outcomes for patients undergoing percutaneous coronary angioplasty at 30 days and at 6 months.

Objective.
—to determine whether abciximab improves outcomes 3 years after coronary angioplasty.

Design.
—Double-blind, placebo-controlled, randomized trial.

Setting.
—A total of 56 academic and community hospitals in the United States.

Patients.
—A total of 2099 high-risk patients undergoing coronary angioplasty were randomized. Sufficient time elapsed for 2.5 years of follow-up among 2001 patients and for 3 years of follow-up among 1599 patients.

Intervention.
—Abciximab bolus of 0.25 mg/kg followed by infusion at 10 µg/min for 12 hours; abciximab bolus of 0.25 mg/kg followed by placebo infusion; or placebo bolus followed by placebo infusion.

Main Outcomes Measures.
—The primary outcome was the composite of death, myocardial infarction, or coronary revascularization. Secondary outcomes were death, myocardial infarction, or coronary revascularization individually. Subgroups having refractory unstable angina or evolving myocardial infarction and having different elevations of creatine kinase during initial angioplasty were analyzed.

Results.
—At 3 years, composite end points occurred in 41.1% of those receiving abciximab bolus plus infusion; 47.4% of those receiving abciximab bolus only; and 47.2% of those receiving placebo only (for abciximab bolus plus infusion vs placebo, P=.009). Death occurred in 6.8%, 8.0%, and 8.6%, respectively (for abciximab bolus plus infusion vs placebo, P=.20); myocardial infarction in 10.7%, 12.2%, and 13.6%, respectively (for abciximab bolus plus infusion vs placebo, P=.08); and revascularization in 34.8%, 38.6%, and 40.1%, respectively (for abciximab bolus plus infusion vs placebo, P=.02). Among those with refractory unstable angina or evolving myocardial infarction, death occurred in 5.1%, 9.2%, and 12.7%, respectively (for abciximab bolus plus infusion vs placebo, P=.01). Death rates increased as periprocedural creatine kinase levels increased.

Conclusions.
—Adciximab bolus with infusion given at the time of coronary angioplasty improves outcomes as long as 3 years after the procedure.

Author Affiliations
for the EPIC Investigator Group

From the Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio (Drs Topol and Ellis and Mr Miller); Baylor College of Medicine (Dr Kleiman) and the Division of Cardiology, Texas Heart Institute (Dr Ferguson), Houston; Florida Heart Group, Orlando (Dr Ivanhoe); Department of Medicine, Duke Clinical Research Institute, Duke University, Durham, NC (Drs Tcheng and Califf); and Centocor, Malvern, Pa (Drs Weisman and Anderson and Ms Wang).

Footnotes
A complete list of the Evaluation of Platelet llb/llla Inhibition for Prevention of Ischemic Complication (EPIC) Investigator Group can be found in Lancet. 1994;343: 881-886.

Reprints: Eric J. Topol, MD, Desk F25, Department of Cardiology, Cleveland Clinic Foundation, Cleveland, OH 44195 (e-mail: topole@cesmtp.ccf.org).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Integrin ₃ Blockade With Abciximab and Protection From Myocardial Ischemic Events
Marcel E. Conrad, Jay N. Umbreit, Elizabeth G. Moore, David L. Fischman, and Michael P. Savage
JAMA. 1998;279(3):195-196.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Prognostic Impact of Periprocedural Bleeding and Myocardial Infarction After Percutaneous Coronary Intervention in Unselected Patients: Results From the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry
Lindsey et al.
J Am Coll Cardiol Intv 2009;2:1074-1082.
ABSTRACT | FULL TEXT  

Effect of the Novel Thienopyridine Prasugrel Compared With Clopidogrel on Spontaneous and Procedural Myocardial Infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38: An Application of the Classification System From the Universal Definition of Myocardial Infarction
Morrow et al.
Circulation 2009;119:2758-2764.
ABSTRACT | FULL TEXT  

The Drug-Eluting Stent Saga
Windecker and Juni
Circulation 2009;119:653-656.
FULL TEXT  

Abciximab for Treatment of Thromboembolic Complications during Endovascular Coiling of Intracranial Aneurysms
Jones et al.
Am. J. Neuroradiol. 2008;29:1925-1929.
ABSTRACT | FULL TEXT  

Survival Benefit With Concomitant Oral Platelet Therapy After Coronary Angiography and Before Ad Hoc Percutaneous Coronary Intervention
Patel and White
Mayo Clin Proc. 2008;83:978-979.
FULL TEXT  

The correlation between lipid volume in the target lesion, measured by integrated backscatter intravascular ultrasound, and post-procedural myocardial infarction in patients with elective stent implantation
Uetani et al.
Eur Heart J 2008;29:1714-1720.
ABSTRACT | FULL TEXT  

Clinical review: gastrointestinal bleeding after percutaneous coronary intervention: a deadly combination
Foley et al.
QJM 2008;101:425-433.
ABSTRACT | FULL TEXT  

ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
Anderson et al.
J Am Coll Cardiol 2007;50:e1-e157.
FULL TEXT  

A Randomized Trial to Evaluate the Relative Protection Against Post-Percutaneous Coronary Intervention Microvascular Dysfunction, Ischemia, and Inflammation Among Antiplatelet and Antithrombotic Agents: The PROTECT-TIMI-30 Trial
Gibson et al.
J Am Coll Cardiol 2006;47:2364-2373.
ABSTRACT | FULL TEXT  

Correlates of Bleeding Events Among Moderate- to High-Risk Patients Undergoing Percutaneous Coronary Intervention and Treated With Eptifibatide: Observations From the PROTECT-TIMI-30 Trial
Kirtane et al.
J Am Coll Cardiol 2006;47:2374-2379.
ABSTRACT | FULL TEXT  

Peri-procedural myocardial injury: 2005 update
Herrmann
Eur Heart J 2005;26:2493-2519.
ABSTRACT | FULL TEXT  

13-year follow-up of the German angioplasty bypass surgery investigation
Kaehler et al.
Eur Heart J 2005;26:2148-2153.
ABSTRACT | FULL TEXT  

Periprocedural Cardiac Enzyme Elevation Predicts Adverse Outcomes
Bhatt and Topol
Circulation 2005;112:906-922.
FULL TEXT  

Role of integrins, including {alpha}8, for neointima formation after vascular injury
Uesugi and Sakata
Cardiovasc Res 2005;65:766-767.
FULL TEXT  

Long-term Efficacy of Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade vs Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Revascularization: REPLACE-2 Randomized Trial
Lincoff et al.
JAMA 2004;292:696-703.
ABSTRACT | FULL TEXT  

Soluble CD40 ligand and platelets: self-perpetuating pathogenic loop in thrombosis and inflammation?
Aukrust et al.
J Am Coll Cardiol 2004;43:2326-2328.
FULL TEXT  

{beta}3-Integrin Mediates Smooth Muscle Cell Accumulation in Neointima After Carotid Ligation in Mice
Choi et al.
Circulation 2004;109:1564-1569.
ABSTRACT | FULL TEXT  

Outcomes with Changes in Prescribing of Glycoprotein IIb/IIIa Inhibitors in PCI
Dobesh et al.
The Annals of Pharmacotherapy 2003;37:1375-1380.
ABSTRACT | FULL TEXT  

Management of Patients Undergoing Percutaneous Coronary Revascularization
Levine et al.
ANN INTERN MED 2003;139:123-136.
ABSTRACT | FULL TEXT  

Use of Abciximab during Infrainguinal Peripheral Vascular Interventions: Initial Experience
Stavropoulos et al.
Radiology 2003;227:657-661.
ABSTRACT | FULL TEXT  

Abciximab-facilitated percutaneous coronary intervention and long-term survival--a prospective single-center registry
Brener et al.
Eur Heart J 2003;24:630-638.
ABSTRACT | FULL TEXT  

Inhibitory Effects of Glycoprotein IIb/IIIa Antagonists and Aspirin on the Release of Soluble CD40 Ligand During Platelet Stimulation
Nannizzi-Alaimo et al.
Circulation 2003;107:1123-1128.
ABSTRACT | FULL TEXT  

Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention: REPLACE-2 Randomized Trial
Lincoff et al.
JAMA 2003;289:853-863.
ABSTRACT | FULL TEXT  

Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA
Lenderink et al.
Eur Heart J 2003;24:77-85.
ABSTRACT | FULL TEXT  

Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: Results of the coronary revascularization using integrilin and single bolus enoxaparin study
Bhatt et al.
J Am Coll Cardiol 2003;41:20-25.
ABSTRACT | FULL TEXT  

Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions
Karvouni et al.
J Am Coll Cardiol 2003;41:26-32.
ABSTRACT | FULL TEXT  

Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality
Brener et al.
J Am Coll Cardiol 2002;40:1961-1967.
ABSTRACT | FULL TEXT  

Pulmonary Hemorrhage After Percutaneous Coronary Intervention With Abciximab Therapy
Choi et al.
Mayo Clin Proc. 2002;77:1340-1343.
ABSTRACT  

Platelet-Derived CD40L: The Switch-Hitting Player of Cardiovascular Disease
Andre et al.
Circulation 2002;106:896-899.
FULL TEXT  

Frequency and long-term impact of myonecrosis after coronary stenting
Brener et al.
Eur Heart J 2002;23:869-876.
ABSTRACT | FULL TEXT  

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
Collaboration
BMJ 2002;324:71-86.
ABSTRACT | FULL TEXT  

The effects of platelet inhibitors on blood use in cardiac surgery
Lee et al.
Perfusion 2002;17:33-37.
ABSTRACT  

Incidence, Predictors, and Significance of Abnormal Cardiac Enzyme Rise in Patients Treated With Bypass Surgery in the Arterial Revascularization Therapies Study (ARTS)
Costa et al.
Circulation 2001;104:2689-2693.
ABSTRACT | FULL TEXT  

Invasive coronary revascularisation is better than conservative treatment in patients with acute coronary syndromes
GONZI et al.
Heart 2001;86:363-364.
FULL TEXT  

Glycoprotein IIb/IIIa inhibitors and acute coronary syndromes: summary report of the full submission to NICE, and beyond
MANOHARAN and ADGEY
Heart 2001;86:259-261.
FULL TEXT  

From bench to bedside: GP IIb-IIIa inhibitors
Fintel
Neurology 2001;57:S12-19.
ABSTRACT | FULL TEXT  

Platelet glycoprotein IIb/IIIa antagonists for acute ischemic stroke
Bogousslavsky and Leclerc
Neurology 2001;57:S53-57.
ABSTRACT | FULL TEXT  

Differential Impact on Survival of Electrocardiographic Q-Wave Versus Enzymatic Myocardial Infarction After Percutaneous Intervention: A Device-Specific Analysis of 7147 Patients
Stone et al.
Circulation 2001;104:642-647.
ABSTRACT | FULL TEXT  

Task Force on Sudden Cardiac Death of the European Society of Cardiology
Priori et al.
Eur Heart J 2001;22:1374-1450.
 

Future Trials of Antiplatelet Agents in Cardiac Ischemia
Throckmorton
NEJM 2001;344:1937-1939.
FULL TEXT  

Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention
Anderson et al.
J Am Coll Cardiol 2001;37:2059-2065.
ABSTRACT | FULL TEXT  

ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines): A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions
Smith et al.
J Am Coll Cardiol 2001;37:2239-2239.
FULL TEXT  

Point-of-Care Measured Platelet Inhibition Correlates With a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention : Results of the GOLD (AU-Assessing Ultegra) Multicenter Study
Steinhubl et al.
Circulation 2001;103:2572-2578.
ABSTRACT | FULL TEXT  

Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function
Lev et al.
J Am Coll Cardiol 2001;37:847-855.
ABSTRACT | FULL TEXT  

Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention
Popma et al.
Chest 2001;119 :321S-336S.
FULL TEXT  

Stents in Total Occlusion for restenosis Prevention. The multicentre randomized STOP study
Lotan et al.
Eur Heart J 2000;21:1960-1966.
ABSTRACT  

A critical appraisal of platelet glycoprotein IIb/IIIa inhibition
Chew and Moliterno
J Am Coll Cardiol 2000;36:2028-2035.
ABSTRACT | FULL TEXT  

Inhibition of vascular smooth muscle cell adhesion and migration by c7E3 Fab (abciximab): a possible mechanism for influencing restenosis
Baron et al.
Cardiovasc Res 2000;48:464-472.
ABSTRACT | FULL TEXT  

Short- and Long-Term Results of Abciximab Versus Aspirin in Conjunction with Thrombolysis for Patients with Peripheral Occlusive Arterial Disease and Arterial Thrombosis
Schweizer et al.
ANGIOLOGY 2000;51:913-923.
ABSTRACT  

Stent magic! The genie has escaped from the bottle
KARSCH and NEWBY
Heart 2000;84:469-470.
FULL TEXT  

Current Role of Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes
Bhatt and Topol
JAMA 2000;284:1549-1558.
ABSTRACT | FULL TEXT  

ACC/AHA guidelines for the management of patients with unstable angina and non-st-segment elevation myocardial infarction: A report of the american college of cardiology/ american heart association task force on practice guidelines (committee on the management of patients with unstable angina)
Braunwald et al.
J Am Coll Cardiol 2000;36:970-1062.
FULL TEXT  

Recent advances in ischaemic heart disease
Cusack et al.
Postgrad. Med. J. 2000;76:542-546.
FULL TEXT  

Management of coronary artery disease: therapeutic options in patients with diabetes
Hammoud et al.
J Am Coll Cardiol 2000;36:355-365.
ABSTRACT | FULL TEXT  

Current status of cardiac surgery in the abciximab-treated patient
Silvestry and Smith
Ann. Thorac. Surg. 2000;70:S12-19.
ABSTRACT | FULL TEXT  

Acute and Delayed Benefits of {beta}-Blockers During Coronary Intervention : True, True and Unrelated
Vetrovec
Circulation 2000;102:147-148.
FULL TEXT  

High Levels of Platelet Inhibition With Abciximab Despite Heightened Platelet Activation and Aggregation During Thrombolysis for Acute Myocardial Infarction : Results From TIMI (Thrombolysis In Myocardial Infarction) 14
Coulter et al.
Circulation 2000;101:2690-2695.
ABSTRACT | FULL TEXT  

Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven?
Lincoff and Topol
Eur Heart J 2000;21:863-867.
 

Smooth Muscle Cell Matrix Metalloproteinase Production Is Stimulated via {alpha}v{beta}3 Integrin
Bendeck et al.
Arterioscler. Thromb. Vasc. Bio. 2000;20:1467-1472.
ABSTRACT | FULL TEXT  

In vitro evaluation of c7E3-Fab (ReoProTM) eluting polymer-coated coronary stents
Baron et al.
Cardiovasc Res 2000;46:585-594.
ABSTRACT | FULL TEXT  

Long-Term Treatment with a Platelet Glycoprotein-Receptor Antagonist after Percutaneous Coronary Revascularization
O'Neill et al.
NEJM 2000;342:1316-1324.
ABSTRACT | FULL TEXT  

Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
Lincoff et al.
J Am Coll Cardiol 2000;35:1103-1115.
ABSTRACT | FULL TEXT  

Inhibition of Neointima Formation After Experimental Coronary Artery Stenting : A New Biodegradable Stent Coating Releasing Hirudin and the Prostacyclin Analogue Iloprost
Alt et al.
Circulation 2000;101:1453-1458.
ABSTRACT | FULL TEXT  

Abciximab reduces mortality in diabetics following percutaneous coronary intervention
Bhatt et al.
J Am Coll Cardiol 2000;35:922-928.
ABSTRACT | FULL TEXT  

Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT
Akkerhuis et al.
Eur Heart J 2000;21:371-381.
ABSTRACT  

Platelets and restenosis
Chandrasekar and Tanguay
J Am Coll Cardiol 2000;35:555-562.
ABSTRACT | FULL TEXT  

Early Percutaneous Coronary Intervention, Platelet Inhibition With Eptifibatide, and Clinical Outcomes in Patients With Acute Coronary Syndromes
Kleiman et al.
Circulation 2000;101:751-757.
ABSTRACT | FULL TEXT  

Atherosclerotic Plaque Burden and CK-MB Enzyme Elevation After Coronary Interventions : Intravascular Ultrasound Study of 2256 Patients
Mehran et al.
Circulation 2000;101:604-610.
ABSTRACT | FULL TEXT  

Recognition of the Importance of Embolization in Atherosclerotic Vascular Disease
Topol and Yadav
Circulation 2000;101:570-580.
FULL TEXT  

Current practice: Antiplatelet use in interventional cardiology
Brodison et al.
Postgrad. Med. J. 2000;76:70-79.
ABSTRACT | FULL TEXT  

Unstable Angina Pectoris
Yeghiazarians et al.
NEJM 2000;342:101-114.
FULL TEXT  

Reviews: Glycoprotein IIb/IIIa Receptor Inhibitors in Acute Coronary Syndromes: Conquests and New Challenges
Smith and Mehta
J CARDIOVASC PHARMACOL THER 2000;5:143-150.
 

Platelet Glycoprotein IIb/IIIa Inhibitors : Basic and Clinical Aspects
Nurden et al.
Arterioscler. Thromb. Vasc. Bio. 1999;19:2835-2840.
FULL TEXT  

Overcoming thrombolytic resistance: Rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction
Cannon
J Am Coll Cardiol 1999;34:1395-1402.
ABSTRACT | FULL TEXT  

Stents in medicine: The role of coronary angioplasty and stenting in acute myocardial infarction
Brodison et al.
Postgrad. Med. J. 1999;75:591-598.
ABSTRACT | FULL TEXT  

Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors
Lincoff et al.
NEJM 1999;341:319-327.
ABSTRACT | FULL TEXT  

Vitaxin, a Humanized Monoclonal Antibody to the Vitronectin Receptor ({alpha}vß3), Reduces Neointimal Hyperplasia and Total Vessel Area After Balloon Injury in Hypercholesterolemic Rabbits
Coleman et al.
Circ. Res. 1999;84:1268-1276.
ABSTRACT | FULL TEXT  

Beneficial Impact of Preconditioning During PTCA on Creatine Kinase Release
Laskey
Circulation 1999;99:2085-2089.
ABSTRACT | FULL TEXT  

Platelet Glycoprotein IIb/IIIa Receptor Antagonists in Cardiovascular Disease
Vorchheimer et al.
JAMA 1999;281:1407-1414.
ABSTRACT | FULL TEXT  

Sustained Suppression of Ischemic Complications of Coronary Intervention by Platelet GP IIb/IIIa Blockade With Abciximab : One-Year Outcome in the EPILOG Trial
Lincoff et al.
Circulation 1999;99:1951-1958.
ABSTRACT | FULL TEXT  

Influence of a platelet GPIIb/IIIa receptor antagonist on myocardial hypoperfusion during rotational atherectomy as assessed by myocardial Tc-99m sestamibi scintigraphy
Koch et al.
J Am Coll Cardiol 1999;33:998-1004.
ABSTRACT | FULL TEXT  

PlA Polymorphism of Platelet Glycoprotein IIIa and Risk of Restenosis After Coronary Stent Placement
Kastrati et al.
Circulation 1999;99:1005-1010.
ABSTRACT | FULL TEXT  

The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: Insights from the EPIC trial
Narins et al.
J Am Coll Cardiol 1999;33:647-653.
ABSTRACT | FULL TEXT  

Glycoprotein IIb/IIIa Integrin Blockade
Madan et al.
Circulation 1998;98:2629-2635.
FULL TEXT  

Abciximab in primary coronary angioplasty for acute myocardial infarction improves short- and medium-term outcomes
Azar et al.
J Am Coll Cardiol 1998;32:1996-2002.
ABSTRACT | FULL TEXT  

Management of Non-Q-Wave Myocardial Infarction
Bedell et al.
NEJM 1998;339:1395-1398.
FULL TEXT  

Frontiers in Interventional Cardiology
Topol and Serruys
Circulation 1998;98:1802-1820.
FULL TEXT  

Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes
The PURSUIT Trial Investigators
NEJM 1998;339:436-443.
ABSTRACT | FULL TEXT  

International, Randomized, Controlled Trial of Lamifiban (a Platelet Glycoprotein IIb/IIIa Inhibitor), Heparin, or Both in Unstable Angina
Circulation 1998;97:2386-2395.
ABSTRACT | FULL TEXT  

ß3-Integrins Rather Than ß1-Integrins Dominate Integrin-Matrix Interactions Involved in Postinjury Smooth Muscle Cell Migration
Slepian et al.
Circulation 1998;97:1818-1827.
ABSTRACT | FULL TEXT  

Management of unstable angina
DTB 1998;36:36-39.
ABSTRACT | FULL TEXT  

Integrin {beta}3 Blockade With Abciximab and Protection From Myocardial Ischemic Events
Conrad et al.
JAMA 1998;279:195-196.
FULL TEXT  

Toward a New Frontier in Myocardial Reperfusion Therapy : Emerging Platelet Preeminence
Topol
Circulation 1998;97:211-218.
FULL TEXT  

Pathophysiological Insight Into the Possible Optimal Therapies for Acute Myocardial Infarction and Unstable Angina
Smalling and Anderson
Circulation 1998;97:10-11.
FULL TEXT  

Murmurs from the heart (or why the stethoscope is not an economic tool)
ARISTIDES et al.
Heart 1998;79:10-11.
FULL TEXT  

Platelet Glycoprotein IIb/IIIa Receptor Blockade after Coronary Angioplasty
Khan et al.
NEJM 1997;337:1243-1245.
FULL TEXT